Individualized Molecular Analyses Guide Efforts (IMAGE): A prospective study of molecular profiling of tissue and blood in metastatic triple-negative breast cancer

Heather A. Parsons, Julia Beaver, Ashley M Cimino-Mathews, Siraj M. Ali, Jennifer Axilbund, David Chu, Roisin Connolly, Rory L. Cochran, Sarah Croessmann, Travis A. Clark, Christopher Gocke, Stacie C. Jeter, Mark R. Kennedy, Josh Lauring, Justin Lee, Doron Lipson, Vincent A. Miller, Geoff A. Otto, Gary Rosner, Jeffrey S. RossShannon Slater, Philip J. Stephens, Dustin A. Vandenberg, Antonio C Wolff, Lauren E. Young, Daniel J. Zabransky, Zhe Zhang, Jane Zorzi, Vered Stearns, Ben H. Park

Research output: Contribution to journalArticle

Abstract

Purpose: The clinical utility of next-generation sequencing (NGS) in breast cancer has not been demonstrated. We hypothesized that we could perform NGS of a new biopsy from patients with metastatic triple-negative breast cancer (TNBC) in a clinically actionable timeframe. Experimental Design: We planned to enroll 40 patients onto a prospective study, Individualized Molecular Analyses Guide Efforts (IMAGE), to evaluate the feasibility of obtaining a new biopsy of a metastatic site, perform NGS (FoundationOne), and convene a molecular tumor board to formulate treatment recommendations within 28 days. We collected blood at baseline and at time of restaging to assess cell-free circulating plasma tumor DNA (ptDNA). Results: We enrolled 26 women with metastatic TNBC who had received ≥1 line of prior chemotherapy, and 20 (77%) underwent NGS of a metastatic site biopsy. Twelve (60%) evaluable patients received treatment recommendations within 28 days of consent. The study closed after 20 patients underwent NGS, based on protocol-specified interim futility analysis. Three patients went on to receive genomically directed therapies. Twenty-four of 26 patients had genetic alterations successfully detected in ptDNA. Among 5 patients, 4 mutations found in tumor tissues were not identified in blood, and 4 mutations found in blood were not found in corresponding tumors. In 9 patients, NGS of follow-up blood samples showed 100% concordance with baseline blood samples. Conclusions: This study demonstrates challenges of performing NGS on prospective tissue biopsies in patients with metastatic TNBC within 28 days, while also highlighting the potential use of blood as a more time-efficient and less invasive method of mutational assessment.

Original languageEnglish (US)
Pages (from-to)379-386
Number of pages8
JournalClinical Cancer Research
Volume23
Issue number2
DOIs
StatePublished - Jan 15 2017

Fingerprint

Triple Negative Breast Neoplasms
Prospective Studies
Biopsy
Neoplasms
Medical Futility
Mutation
DNA
Research Design
Therapeutics
Breast Neoplasms
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Individualized Molecular Analyses Guide Efforts (IMAGE) : A prospective study of molecular profiling of tissue and blood in metastatic triple-negative breast cancer. / Parsons, Heather A.; Beaver, Julia; Cimino-Mathews, Ashley M; Ali, Siraj M.; Axilbund, Jennifer; Chu, David; Connolly, Roisin; Cochran, Rory L.; Croessmann, Sarah; Clark, Travis A.; Gocke, Christopher; Jeter, Stacie C.; Kennedy, Mark R.; Lauring, Josh; Lee, Justin; Lipson, Doron; Miller, Vincent A.; Otto, Geoff A.; Rosner, Gary; Ross, Jeffrey S.; Slater, Shannon; Stephens, Philip J.; Vandenberg, Dustin A.; Wolff, Antonio C; Young, Lauren E.; Zabransky, Daniel J.; Zhang, Zhe; Zorzi, Jane; Stearns, Vered; Park, Ben H.

In: Clinical Cancer Research, Vol. 23, No. 2, 15.01.2017, p. 379-386.

Research output: Contribution to journalArticle

Parsons, HA, Beaver, J, Cimino-Mathews, AM, Ali, SM, Axilbund, J, Chu, D, Connolly, R, Cochran, RL, Croessmann, S, Clark, TA, Gocke, C, Jeter, SC, Kennedy, MR, Lauring, J, Lee, J, Lipson, D, Miller, VA, Otto, GA, Rosner, G, Ross, JS, Slater, S, Stephens, PJ, Vandenberg, DA, Wolff, AC, Young, LE, Zabransky, DJ, Zhang, Z, Zorzi, J, Stearns, V & Park, BH 2017, 'Individualized Molecular Analyses Guide Efforts (IMAGE): A prospective study of molecular profiling of tissue and blood in metastatic triple-negative breast cancer', Clinical Cancer Research, vol. 23, no. 2, pp. 379-386. https://doi.org/10.1158/1078-0432.CCR-16-1543
Parsons, Heather A. ; Beaver, Julia ; Cimino-Mathews, Ashley M ; Ali, Siraj M. ; Axilbund, Jennifer ; Chu, David ; Connolly, Roisin ; Cochran, Rory L. ; Croessmann, Sarah ; Clark, Travis A. ; Gocke, Christopher ; Jeter, Stacie C. ; Kennedy, Mark R. ; Lauring, Josh ; Lee, Justin ; Lipson, Doron ; Miller, Vincent A. ; Otto, Geoff A. ; Rosner, Gary ; Ross, Jeffrey S. ; Slater, Shannon ; Stephens, Philip J. ; Vandenberg, Dustin A. ; Wolff, Antonio C ; Young, Lauren E. ; Zabransky, Daniel J. ; Zhang, Zhe ; Zorzi, Jane ; Stearns, Vered ; Park, Ben H. / Individualized Molecular Analyses Guide Efforts (IMAGE) : A prospective study of molecular profiling of tissue and blood in metastatic triple-negative breast cancer. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 2. pp. 379-386.
@article{7103d6d620534cdf9e8fe6739545e52a,
title = "Individualized Molecular Analyses Guide Efforts (IMAGE): A prospective study of molecular profiling of tissue and blood in metastatic triple-negative breast cancer",
abstract = "Purpose: The clinical utility of next-generation sequencing (NGS) in breast cancer has not been demonstrated. We hypothesized that we could perform NGS of a new biopsy from patients with metastatic triple-negative breast cancer (TNBC) in a clinically actionable timeframe. Experimental Design: We planned to enroll 40 patients onto a prospective study, Individualized Molecular Analyses Guide Efforts (IMAGE), to evaluate the feasibility of obtaining a new biopsy of a metastatic site, perform NGS (FoundationOne), and convene a molecular tumor board to formulate treatment recommendations within 28 days. We collected blood at baseline and at time of restaging to assess cell-free circulating plasma tumor DNA (ptDNA). Results: We enrolled 26 women with metastatic TNBC who had received ≥1 line of prior chemotherapy, and 20 (77{\%}) underwent NGS of a metastatic site biopsy. Twelve (60{\%}) evaluable patients received treatment recommendations within 28 days of consent. The study closed after 20 patients underwent NGS, based on protocol-specified interim futility analysis. Three patients went on to receive genomically directed therapies. Twenty-four of 26 patients had genetic alterations successfully detected in ptDNA. Among 5 patients, 4 mutations found in tumor tissues were not identified in blood, and 4 mutations found in blood were not found in corresponding tumors. In 9 patients, NGS of follow-up blood samples showed 100{\%} concordance with baseline blood samples. Conclusions: This study demonstrates challenges of performing NGS on prospective tissue biopsies in patients with metastatic TNBC within 28 days, while also highlighting the potential use of blood as a more time-efficient and less invasive method of mutational assessment.",
author = "Parsons, {Heather A.} and Julia Beaver and Cimino-Mathews, {Ashley M} and Ali, {Siraj M.} and Jennifer Axilbund and David Chu and Roisin Connolly and Cochran, {Rory L.} and Sarah Croessmann and Clark, {Travis A.} and Christopher Gocke and Jeter, {Stacie C.} and Kennedy, {Mark R.} and Josh Lauring and Justin Lee and Doron Lipson and Miller, {Vincent A.} and Otto, {Geoff A.} and Gary Rosner and Ross, {Jeffrey S.} and Shannon Slater and Stephens, {Philip J.} and Vandenberg, {Dustin A.} and Wolff, {Antonio C} and Young, {Lauren E.} and Zabransky, {Daniel J.} and Zhe Zhang and Jane Zorzi and Vered Stearns and Park, {Ben H.}",
year = "2017",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-16-1543",
language = "English (US)",
volume = "23",
pages = "379--386",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Individualized Molecular Analyses Guide Efforts (IMAGE)

T2 - A prospective study of molecular profiling of tissue and blood in metastatic triple-negative breast cancer

AU - Parsons, Heather A.

AU - Beaver, Julia

AU - Cimino-Mathews, Ashley M

AU - Ali, Siraj M.

AU - Axilbund, Jennifer

AU - Chu, David

AU - Connolly, Roisin

AU - Cochran, Rory L.

AU - Croessmann, Sarah

AU - Clark, Travis A.

AU - Gocke, Christopher

AU - Jeter, Stacie C.

AU - Kennedy, Mark R.

AU - Lauring, Josh

AU - Lee, Justin

AU - Lipson, Doron

AU - Miller, Vincent A.

AU - Otto, Geoff A.

AU - Rosner, Gary

AU - Ross, Jeffrey S.

AU - Slater, Shannon

AU - Stephens, Philip J.

AU - Vandenberg, Dustin A.

AU - Wolff, Antonio C

AU - Young, Lauren E.

AU - Zabransky, Daniel J.

AU - Zhang, Zhe

AU - Zorzi, Jane

AU - Stearns, Vered

AU - Park, Ben H.

PY - 2017/1/15

Y1 - 2017/1/15

N2 - Purpose: The clinical utility of next-generation sequencing (NGS) in breast cancer has not been demonstrated. We hypothesized that we could perform NGS of a new biopsy from patients with metastatic triple-negative breast cancer (TNBC) in a clinically actionable timeframe. Experimental Design: We planned to enroll 40 patients onto a prospective study, Individualized Molecular Analyses Guide Efforts (IMAGE), to evaluate the feasibility of obtaining a new biopsy of a metastatic site, perform NGS (FoundationOne), and convene a molecular tumor board to formulate treatment recommendations within 28 days. We collected blood at baseline and at time of restaging to assess cell-free circulating plasma tumor DNA (ptDNA). Results: We enrolled 26 women with metastatic TNBC who had received ≥1 line of prior chemotherapy, and 20 (77%) underwent NGS of a metastatic site biopsy. Twelve (60%) evaluable patients received treatment recommendations within 28 days of consent. The study closed after 20 patients underwent NGS, based on protocol-specified interim futility analysis. Three patients went on to receive genomically directed therapies. Twenty-four of 26 patients had genetic alterations successfully detected in ptDNA. Among 5 patients, 4 mutations found in tumor tissues were not identified in blood, and 4 mutations found in blood were not found in corresponding tumors. In 9 patients, NGS of follow-up blood samples showed 100% concordance with baseline blood samples. Conclusions: This study demonstrates challenges of performing NGS on prospective tissue biopsies in patients with metastatic TNBC within 28 days, while also highlighting the potential use of blood as a more time-efficient and less invasive method of mutational assessment.

AB - Purpose: The clinical utility of next-generation sequencing (NGS) in breast cancer has not been demonstrated. We hypothesized that we could perform NGS of a new biopsy from patients with metastatic triple-negative breast cancer (TNBC) in a clinically actionable timeframe. Experimental Design: We planned to enroll 40 patients onto a prospective study, Individualized Molecular Analyses Guide Efforts (IMAGE), to evaluate the feasibility of obtaining a new biopsy of a metastatic site, perform NGS (FoundationOne), and convene a molecular tumor board to formulate treatment recommendations within 28 days. We collected blood at baseline and at time of restaging to assess cell-free circulating plasma tumor DNA (ptDNA). Results: We enrolled 26 women with metastatic TNBC who had received ≥1 line of prior chemotherapy, and 20 (77%) underwent NGS of a metastatic site biopsy. Twelve (60%) evaluable patients received treatment recommendations within 28 days of consent. The study closed after 20 patients underwent NGS, based on protocol-specified interim futility analysis. Three patients went on to receive genomically directed therapies. Twenty-four of 26 patients had genetic alterations successfully detected in ptDNA. Among 5 patients, 4 mutations found in tumor tissues were not identified in blood, and 4 mutations found in blood were not found in corresponding tumors. In 9 patients, NGS of follow-up blood samples showed 100% concordance with baseline blood samples. Conclusions: This study demonstrates challenges of performing NGS on prospective tissue biopsies in patients with metastatic TNBC within 28 days, while also highlighting the potential use of blood as a more time-efficient and less invasive method of mutational assessment.

UR - http://www.scopus.com/inward/record.url?scp=85011003350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011003350&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-1543

DO - 10.1158/1078-0432.CCR-16-1543

M3 - Article

C2 - 27489289

AN - SCOPUS:85011003350

VL - 23

SP - 379

EP - 386

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -